(Nasdaq: MRNS) showcased new findings from its pivotal Phase 3 RAISE trial at the Neurocritical Care Society Annual Meeting, highlighting the potential of intravenous (IV) ganaxolone in treating ...

Marinus Pharmaceuticals has announced that its pivotal Phase III RAISE study (NCT04391569) of IV ganaxolone for the treatment of status epilepticus (SE) has failed to meet its pre-defined early ...